HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

Arvinas’ ‘Protac’ breast cancer drug cleared by FDA

Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for a new partner to sell it.

By BioPharma Dive · May 1, 2026 · via BioPharma Dive
Arvinas’ ‘Protac’ breast cancer drug cleared by FDA

Image: BioPharma Dive

This is an aggregated industry headline. Read the full story at BioPharma Dive →

Tags
pipelineformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal
PipelineFierceBiotech ↗
AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal
An FDA expert panel on Thursday voted 6 to 3 against AstraZeneca's proposal of using its oral SERD camizestran…
May 2, 2026
Axsome Wins Second Auvelity Approval, Targeting Alzheimer’s Agitation
PipelineBriefing
Axsome Wins Second Auvelity Approval, Targeting Alzheimer’s Agitation
FDA authorizes Auvelity for agitation tied to Alzheimer’s disease, positioning Axsome’s NMDA/sigma-1 modulator…
May 2, 2026
FDA flags concerns for AstraZeneca's camizestrant, Truqap ahead of advisory committee meeting
PipelineFiercePharma ↗
FDA flags concerns for AstraZeneca's camizestrant, Truqap ahead of advisory committee meeting
The FDA has released briefing documents detailing its concerns for AstraZeneca’s cancer drugs camizestrant and…
May 1, 2026